850607-53-3

Upstream product

• 1131911-30-2 3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropanenitrile trifluoroacetate 
• 852460-98-1 [(3-endo)-8-(phenylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]methanol 
• 273376-39-9 tert-butyl rel-(1R,3r,5S)-3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 56880-11-6 ethyl endo-8-methyl-8-azabicyclo<3.2.1>oct-3-ylacetate 
• 591-51-5 phenyllithium 
• 924646-52-6 methyl (3-endo)-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)acetate 
• 7677-24-9 trimethylsilyl cyanide 
• 95131-86-5 2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1,1-diphenylethanol 
• 850607-72-6 (3-endo)-3-iodomethyl-8-methyl-8-azabicyclo[3.2.1]octane 
• 86-29-3 Diphenylacetonitrile 

Downstream Products

• 852461-01-9 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-(cyclohexylmethyl)-8-methyl-8-azoniabicyclo[3.2.1]octane bromide 
• 1131911-30-2 3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropanenitrile trifluoroacetate 
• 850607-58-8 Darotropium bromide 
• 852461-12-2 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-(3-cyanopropyl)-8-methyl-8-azoniabicyclo[3.2.1]octane bromide 
• 852461-08-6 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-(2-hydroxyethyl)-8-methyl-8-azoniabicyclo[3.2.1]octane bromide 
• 852461-13-3 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-[2-(methoxy)ethyl]-8-azoniabicyclo[3.2.1]octane bromide 
• 1374305-23-3 Br^(1-)*C₂₇H₃₃N₂⁽¹⁺⁾ 
• 1374305-29-9 Br^(1-)*C₂₉H₃₇N₂⁽¹⁺⁾ 
• 852461-05-3 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-dodecyl-8-methyl-8-azoniabicyclo[3.2.1]octane bromide 
• 852461-10-0 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-propyl-8-azoniabicyclo[3.2.1]octane bromide 
• 852461-07-5 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(phenylmethyl)-8-azoniabicvclo[3.2.1]octane bromide 
• 852461-14-4 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(2-{[2-(methoxy)ethyl]oxy}ethyl)-8-azoniabicyclo[3.2.1]octane bromide 
• 852461-11-1 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-(cyclohexylethyl)-8-methyl-8-azoniabicyclo[3.2.1]octane bromide 
• 852461-06-4 (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(2-propen-1-yl)-8-azoniabicyclo[3.2.1]octane iodide 

Relevant academic research and scientific papers

Development of synthetic routes, via a tropinone intermediate, to a long-acting muscarinic antagonist for the treatment of respiratory disease

This contribution describes the development of two synthetic routes to an investigational muscarinic antagonist for the treatment of chronic obstructive pulmonary disease. The first route used a starting material which was in plentiful supply within the GSK network and was used to make material for early clinical trials and safety assessment studies. Further investigations identified a second, potential long-term manufacturing route from commercially available building blocks, using substrate control to install the two stereocentres with excellent selectivity. A key step was a substrate-directed epoxide reduction which also gave rise to a minor byproduct through a skeletal rearrangement of the tropane ring. A deuterium-labeling experiment was carried out, which shed light on the origin of the byproduct, and also guided the improvement of reaction conditions.

Design, synthesis, and structure - Activity relationship of tropane muscarinic acetylcholine receptor antagonists

Novel tropane derivatives were characterized as muscarinic acetylcholine receptor antagonists (mAChRs). Through optimization of the structure - activity relationship around the tropane scaffold, the quaternary ammonium salt 34 was identified as a very pot

Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD

Design and syntheses of a novel series of muscarinic antagonists are reported. These efforts have culminated in the discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide (4a) as a potent and pan-active musca

NOVEL COMBINATION OF THERAPEUTIC AGENTS

Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist and/or a corticosteroid for inhaled administration via the nose or mouth, and methods of using them are provided herein.

M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.